HRS-6768

· Jiangsu HengRui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HRS-6768, covering 2025-12-03 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: A Trial of HRS-6768 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]